CytomX Therapeutics (CTMX) Misses Q3 EPS by 4c

CytomX Therapeutics (NASDAQ: CTMX) reported Q3 EPS of ($0.09), $0.04 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $5.9 million versus the consensus estimate of $11.84 million.

For earnings history and earnings-related data on CytomX Therapeutics (CTMX) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Cboe launches binary options suite tied to Mini-S&P 500 Index
• Sony Semiconductor Solutions unveils 64MP mobile image sensor